LAVA Therapeutics NVNASDAQ:LVTX
- LAST PRICE1.5900
- TODAY'S CHANGE (%)-0.0200 (-1.2422%)
- Bid / Lots1.5900/ 27
- Ask / Lots1.6300/ 2
- Open / Previous Close1.6300 / 1.6100
- Day Range
- 52 Week Range
- Volume32,905
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LVTX |
|---|---|---|
| 09:32 ET | 1441 | 1.63 |
| 09:33 ET | 200 | 1.65 |
| 09:35 ET | 200 | 1.65 |
| 09:37 ET | 200 | 1.65 |
| 09:42 ET | 890 | 1.65 |
| 09:51 ET | 300 | 1.64 |
| 10:08 ET | 1000 | 1.625 |
| 10:20 ET | 1000 | 1.6299 |
| 10:27 ET | 200 | 1.63 |
| 10:36 ET | 500 | 1.6201 |
| 10:58 ET | 600 | 1.62 |
| 11:02 ET | 130 | 1.6153 |
| 11:07 ET | 500 | 1.629 |
| 11:20 ET | 500 | 1.6286 |
| 11:23 ET | 200 | 1.63 |
| 11:36 ET | 950 | 1.64 |
| 12:10 ET | 700 | 1.61 |
| 12:19 ET | 7374 | 1.63 |
| 12:30 ET | 1592 | 1.62 |
| 12:33 ET | 100 | 1.62 |
| 12:37 ET | 4923 | 1.63 |
| 12:42 ET | 100 | 1.6358 |
| 12:50 ET | 200 | 1.625 |
| 12:57 ET | 200 | 1.625 |
| 01:06 ET | 200 | 1.625 |
| 01:09 ET | 855 | 1.68 |
| 01:24 ET | 200 | 1.629 |
| 01:31 ET | 200 | 1.622 |
| 01:38 ET | 100 | 1.63 |
| 01:40 ET | 100 | 1.63 |
| 01:49 ET | 100 | 1.625 |
| 01:58 ET | 200 | 1.63 |
| 02:07 ET | 200 | 1.61 |
| 02:16 ET | 200 | 1.61 |
| 02:23 ET | 300 | 1.61 |
| 02:34 ET | 200 | 1.6 |
| 02:39 ET | 1100 | 1.6 |
| 02:41 ET | 145 | 1.6 |
| 02:50 ET | 145 | 1.6 |
| 02:57 ET | 1000 | 1.59 |
| 02:59 ET | 200 | 1.59 |
| 03:01 ET | 100 | 1.595 |
| 03:08 ET | 200 | 1.59 |
| 03:15 ET | 453 | 1.59 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
LAVA Therapeutics NV | 42.1M | -1.8x | --- |
Tonix Pharmaceuticals Holding Corp | 35.5M | 0.0x | --- |
Affimed NV | 39.9M | -0.6x | --- |
Kezar Life Sciences Inc | 54.7M | -0.6x | --- |
Kronos Bio Inc | 54.4M | -0.6x | --- |
DURECT Corp | 31.3M | -1.7x | --- |
Company Information
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Contact Information
- Headquarters
- Yalelaan 60UTRECHT, Netherlands 3584 CM
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Kapil Dhingra
- President, Chief Executive Officer, Management Director
- Stephen Hurly
- Chief Financial Officer
- Edward Smith
- Executive Vice President Head of Research and Development
- Paul Parren
- Chief Scientific Officer
- Hans Van Der Vliet
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $42.1M |
|---|---|
Revenue (TTM) | $7.4M |
Shares Outstanding | 26.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.43 |
EPS | $-0.90 |
Book Value | $1.95 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | 5.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -371.48% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
